Abstracts

To participate in ESCMID Global as a presenter, submit abstracts of your original research or case report/series to be included in the abstract programme.

Here you can find all information on how to submit your abstract and become one of the thousands of researchers presenting at ESCMID Global.

Abstract Book 2026

The official ESCMID Global 2026 abstract book, featuring all accepted and presented abstracts.

Download (PDF, 650 MB)

Submission

Abstract submission for ESCMID Global 2027 will be open from 07 October – 18 November 2026.

Please note that we do not guarantee that the submission deadline will be extended and we will not accept any submission after the deadline.

Important information for submitters

You can use our online abstract submission platform to craft and revise your abstract in a draft mode before final submission. Once your abstract is submitted, you cannot implement any changes.
Please assign your abstract to the correct category/subcategory.
Your abstract should be no longer than 350 words, including the title. (regular abstract: background, methods, results and conclusion; Case report/series: background, case(s) description, discussion)
You will be able to upload up to three figures/tables. Please make sure those are uploaded correctly before the final submission and that each uploaded figure has a title.
Abstracts submitted to ESCMID Global must be based on novel data not previously presented or published.
The ESCMID Global Programme Committee reserves the right to reject submitted abstracts if the data have been published in an international journal, earlier than six weeks before the congress.
All abstracts will undergo peer review by at least three reviewers, evaluating them for relevance, methodology, scientific quality, novelty, clarity, and presentation. The results of the review will be communicated to presenting authors in the last week of January 2027.

The following policies are aligned with the ICMJE Recommendations on the use of artificial intelligence in scientific publishing:

Abstracts must not contain AI-generated data or results presented as if they were derived from actual research. The legitimate use of AI as part of the research methodology is permitted and should be appropriately described.
AI tools may be used to assist with the writing or editing of an abstract.
Authors remain fully responsible for the accuracy, originality, and integrity of all submitted content, for appropriate citation of sources, and for ensuring that plagiarism has not occurred. AI-generated material must not be cited as a primary source.

Abstract categories

Abstracts are grouped according to the list of 13 categories below and their respective subcategories. Explore the list and determine which categories and subcategories your abstracts fall under before you submit as this determines the topic under which your abstract will be presented.

1. Viral infection & disease (incl COVID-19)

1a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)
1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)
1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance) 
1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)
1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)
1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV; incl traditional, molecular, genomic and other methods)
1g. Viral epidemiology – general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)
1h. Antiviral drugs, treatment, susceptibility/resistance (other than respiratory viruses, herpesviruses, hepatitis & HIV)
1i. Fundamental and applied virology (incl in vitro and in vivo models, novel methods)
1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

2. Bacterial infection & disease

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)
2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host biomarkers, treatment, and outcome prediction)
2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)
2d. Community-acquired abdominal/gastrointestinal infections (incl epidemiology, clinical, imaging, treatment & prevention)
2e. Community-acquired urinary tract & genital tract infections (incl epidemiology, clinical, imaging, treatment & prevention)
2f. Community-acquired skin, soft tissue, bone & joint infections (incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses) 
2g. Community-acquired nervous system and other multi-system or invasive bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)
2h. Zoonotic bacterial infections (incl vector-borne pathogens, excl AMR)
2i. Other intracellular or rare bacteria

3. Bacterial susceptibility & resistance

3a. Resistance surveillance & epidemiology: Community-acquired bacteria
3b. Resistance surveillance & epidemiology: Healthcare-associated bacteria
3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)
3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)
3e. Resistance detection/prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)
3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs, excl case series)
3g. Spread of resistance (incl carriage, reservoirs, ecology, One Health models, excl nosocomial transmission)
3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

4. Diagnostic microbiology

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)
4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)
4c. MALDI-TOF and other proteomic methods
4d. Molecular diagnostics (incl POCT and syndromic testing)
4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)
4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing) 
4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects, excl fundamental science)
4h. Clinical metagenomics
4i. Bioinformatics tools & pipelines
4j. Artificial intelligence based tools and digital health
4k. Other novel diagnostic technologies

5. New antibacterial agents, PK/PD & stewardship

5a. Drug discovery and new compounds mechanisms of action & spectrum, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)
5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)
5c. New or repurposed antibacterial agents: Clinical studies and randomised trials
5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support/prediction tools, behavioural aspects)
5e. Safety, hypersensitivity and adverse effects of treatment
5f. Pharmacoepidemiology/pharmacoeconomics (incl cost-effectiveness, modelling, data tools)

6. Fungal infection & disease

6a. Fundamental mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)
6b. Fungal disease epidemiology 
6c. Diagnostic mycology (incl traditional, molecular and other methods)
6d. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)
6e. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

7. Parasitic diseases, travel medicine & migrant health

7a. Fundamental parasitology
7b. Parasitic disease epidemiology
7c. Diagnostic parasitology (incl traditional, molecular and genomic methods)
7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)
7e. Antiparasitic susceptibility & drug resistance (incl surveillance, mechanism)
7f. Travel medicine, migrant and refugee health

8. Healthcare-associated infections, infection prevention & control

8a. Intravascular catheter-related infections (incl epidemiology, prevention)
8b. Other foreign-body and implant-associated infections (incl PJI)
8c. Surgical site infections
8d. Healthcare-associated pneumonia (incl VAP)
8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment) 
8f. Other healthcare associated infections (incl CDI, hospital outbreaks)
8g. Infection control interventions and trials (incl microbiota transplantation)
8h. Disinfection & sterilisation (incl medical device reprocessing)
8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

9. Fundamental microbiology, pathogenesis & immunity to infection

9a. Microbial pathogenesis & virulence
9b. Host-pathogen interaction (incl basic microbiome studies, animal models)
9c. Pre-clinical biofilm studies
9d. Experimental and cellular microbiology 
9e. Fundamental science studies using Omics (in vitro and in vivo)
9f. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

10. Immune compromise & transplant ID

10a. Host genetics: Susceptibility to infection & primary immunodeficiency
10b. Infections related to solid organ transplantation
10c. Infections related to haematopoietic stem cell transplantation
10d. Infections related to cell-based therapies
10e. Infections related to cancer treatment (incl neutropaenia)
10f. Infections related to other forms of immunosuppression (e.g. gastrointestinal, rheumatological, dermatological disease, biologicals)

11. Public health & vaccines

11a. General vaccinology (incl in vitro and in vivo studies, safety, regulatory, policy, social aspects)
11b. Antiviral vaccines (excl respiratory and bloodborne viruses)
11c. Antibacterial vaccines
11d. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)
11e. Food & water safety, environmental health, vector epidemiology
11f. Veterinary microbiology and One Health (excl AMR)
11g. Global health & health security (incl policy-making, climate change, biosafety/biosecurity)
11h. Infections in low-resource settings (incl disease burden, health infrastructure, health disparities and vulnerable populations)

12. Professional and educational affairs

12a. Professional affairs and career development
12b. Publishing, ethics, other academic affairs
12c. Medical education for CM/ID
12d. Diversity and equality
12e. Advocacy and role of patients

13. Case reports and case series (n<10)

13a. Viral infections
13b. Bacterial infections
13c. Fungal infections
13d. Parasitic infections
13e. Other unusual clinical situations

Grants & awards

ESCMID offers a number of travel grants that specifically support abstract presenters in attending ESCMID Global. Additionally, awards are available for exceptional abstracts.

FAQ

Is it mandatory to be an ESCMID member to submit an abstract to ESCMID Global?

No it is not mandatory to be an ESCMID member. But if you are not a member you need an ESCMID web user account that can be created here at no cost.

Do I need to register for ESCMID Global before submitting my abstract?

You do not need to register for ESCMID Global to submit an abstract. The only requirement is that the submitter has an ESCMID web user account or an ESCMID member account. If the abstract is accepted, the presenting author must register for the congress to be eligible for the abstract's publication and presentation.

Do I need to attend ESCMID Global onsite to present my abstract?

If your abstract is accepted, you can attend ESCMID Global onsite or online with a valid registration to present your work.

Are agencies allowed to submit abstracts on behalf of the authors?

Yes, agencies can submit abstracts.

How many abstracts can be submitted by a single author?

There is no limit on the number of abstracts that one author can submit.

I have trouble logging in. Where can I seek assistance with a forgotten password or other account-related question?

It is only possible to log in with your ESCMID credentials. Changes to your account or password resets can be done on the ESCMID website here.

Are abstracts of narrative literature review accepted for submission?

Systematic reviews/meta-analyses or case report/series complemented by a literature review can be accepted. Narrative literature reviews are discouraged.

Are case reports/series accepted for submission?

Yes, case reports/series can be submitted.

Does ESCMID provide a consent form for case reports? Who is responsible for obtaining patients’ consent before presenting the case report?

ESCMID does not provide a consent form. The abstract author is responsible for ensuring that all necessary consents and disclosures are collected within all applicable laws and guidelines.

Are study design abstracts accepted for submission?

ESCMID discourages submissions not featuring original data.

Are abstracts on ‘Trials in Progress’ accepted for submission?

For ‘Trial in Progress’, in which results are expected after the regular abstract deadline, please submit your abstract, including results, during the late-breaking abstract call.

Are abstracts on national public health policies accepted for submission, for example reimbursement policies?

Yes, abstracts on national policies are accepted, even if they only focus on a single country (no geographic restrictions).

We are about to launch a public health alert via a briefing note or public health bulletin – would it still be possible to submit an abstract on the incident in a wider context and including additional data?

Yes.

Are abstracts in which only a part of the results are published before ESCMID Global accepted?

Yes. Please clarify that in the abstract.

Can abstracts include brand names?

Company names must not be used in titles (ESCMID has the right to remove it from the title during approval process). Specific product names in titles should be avoided.

Are encore abstract submissions allowed?

Encore abstracts are not accepted for ESCMID Global. Only original unpublished material is allowed. Abstracts with published data may be considered only if there is substantial new data or analysis included.

How can I delete my abstract?

If your abstract is in draft mode, you can log in to the system and delete it yourself. If the review has begun, you will need to wait for the outcome, and if abstracts are accepted, you can then use the contact form below for the withdrawal.

Is it possible to change the names of authors of the abstract?

It is the responsibility of the submitter to ensure that the names of author(s) and their affiliation(s) are correctly spelled and formatted with appropriate capitalisation and punctuation.

Names and affiliations cannot be edited by the submitter once submission is complete and will be published exactly as submitted.

ESCMID takes no responsibility for errors in either author or affiliation information. For any changes, please contact the ESCMID office.

What size should any figures or tables be?

Maximum file size: 4.88 MB

Maximum height and width: 1000 x 1000 pixels.

Accepted file formats: PNG, BMP, GIF, JPG, JPEG

When will the embargo be lifted for the content of accepted abstracts?

The embargo will be lifted 10 days before the start of ESCMID Global.

How do I apply for the ESCMID Global Travel Grant?

Please provide all relevant information required for the grant application during the submission of your abstract and indicate that you would like to be included in the selection pool.

I forgot to apply for the travel grant. Can I apply for it retrospectively?

Once the abstract is submitted, no more changes are possible.

I mistakenly applied for the travel grant. Can I withdraw my application?

Once the abstract is submitted, no more changes are possible.

Contact

Looking for more information? Get in touch with an ESCMID representative today!

Contact form